BeiGene is a global, commercial stage biotechnology company focused on researching, developing, producing, and commercializing innovative drugs. The company has 11 independently developed drugs entering clinical trials or commercialization stage, including 3 products approved for market launch.

 

 

 

Financial data shows that BeiGene has been experiencing significant losses in recent years. From 2018 to 2020, the company's operating revenue was 1.31 billion yuan, 2.954 billion yuan, and 2.12 billion yuan, respectively, with year-on-year growth of -18.67%, 125.49%, and -28.23%; The net profit attributable to the parent company was -47.47 billion yuan, -6.915 billion yuan, and -113.384 billion yuan, respectively, an increase of -383.51%, -45.67%, and -64.63% year-on-year. However, the company's R&D expenses have been increasing year by year, with R&D expenses of 4.597 billion yuan, 6.588 billion yuan, and 8.943 billion yuan respectively during the same period.

 

 

 

2024 is a crucial turning point for BeiGene, mainly due to the sales growth of Beiyue Ze, as well as authorized products from Anjin and Beize An. The annual performance report showed that the company's product revenue was 26.994 billion yuan, a year-on-year increase of 74.1%; The total operating revenue was 27.214 billion yuan, an increase of 56.2% year-on-year; The net profit attributable to the owners of the parent company was a loss of 4.978 billion yuan, a year-on-year decrease of 25.87%. At the same time, the company provided financial guidance for the first time in its US stock earnings report, stating that its total revenue for the full year of 2025 will be between $4.9 billion and $5.3 billion, including expectations of strong revenue growth, benefiting from the company's position in the United States and its continued expansion in other important markets in Europe and around the world. And reiterate the expectation to achieve GAAP (Generally Accepted Accounting Principles) positive operating profit and positive cash flow from operating activities by 2025.

 

 

 

It is worth mentioning that among the 8 pharmaceutical stocks with a market value of billions, two are traditional Chinese medicine stocks, namely Pianzaihuang and Yunnan Baiyao. Among them, the market value of Pien Tze Huang is 122 billion yuan. Recently, the company disclosed its 2024 performance report, which showed that the company achieved a total operating revenue of 10.769 billion yuan in 2024, a year-on-year increase of 7.06%; The net profit attributable to shareholders of the listed company reached 2.974 billion yuan, a year-on-year increase of 6.32%. The company pointed out that the growth of its total operating revenue is mainly due to the company's strengthening of market planning and expansion of sales channels. The sales of its core products, the Pien Tze Huang series products and the Pien Tze Huang brand Angong Niuhuang Wan, have increased. However, due to changes in medical insurance policies and a decrease in the consumer market, the revenue of the pharmaceutical distribution industry decreased year-on-year. After deducting the pharmaceutical distribution industry, the company's total operating revenue increased by 13.29% year-on-year.

 

 

 

The market value of Yunnan Baiyao is 101.3 billion yuan. The company's disclosed 2024 annual report shows that it achieved a revenue of 40.033 billion yuan, a year-on-year increase of 2.36%; The net profit attributable to the parent company was 4.749 billion yuan, a year-on-year increase of 16.02%. At present, the company is committed to promoting sustained growth of the enterprise and has established short-term, medium-term, and long-term research and development growth strategies. In the short term, the company will promote the rapid growth of potential varieties such as Qi Qi Kang, Gong Xue Ning, and Yunnan Baiyao Capsules through secondary innovation and development of listed varieties, as well as drug and device development; In the medium term, we will promote the development of innovative traditional Chinese medicine; In terms of long-term development, the company will develop the large blue ocean market of nuclear medicine products. Data shows that the size of China's nuclear drug market is expected to reach 26 billion yuan by 2025, with a compound annual growth rate of 21.6%, indicating enormous market development potential.